Compass Therapeutics, Inc. CMPX
0.75 USD -0.01 (-1.89%)
At closeNov 3, 2026, 7:38 PM EST
0.77 +0.02 +1.99%
After hours · Nov 3, 7:38 PM ET
0.7444 Day range 0.7922
0.73 52-week range 6.88
- YTD
- -85.98%
- 1 year
- -79.87%
News
globenewswire.com Compass Therapeutics to Participate in Upcoming November Investor Events BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…
globenewswire.com Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026 BOSTON, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…
globenewswire.com Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…
benzinga.com This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday Wall Street analysts downgraded Rollins, Yum Brands, Alkami Technology, VICI Properties and Safehold, cutting targets for Rollins and Alkami.
benzinga.com Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8 Craig-Hallum analyst Albert Lowe maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $15 to $8.
seekingalpha.com Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity Compass Therapeutics faces a major setback after tovecimig failed to show an overall survival benefit in biliary tract cancer. CMPX plans to pursue a BLA submission for tovecimig despite FDA guidance…
benzinga.com This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.
benzinga.com Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4 Citizens analyst Reni J. Benjamin maintains Compass Therapeutics (NASDAQ:CMPX) with a Market Outperform and lowers the price target from $10 to $4.
benzinga.com Guggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4 Guggenheim analyst Michael Schmidt maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $8 to $4.
benzinga.com Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1 Wedbush analyst Robert Driscoll downgrades Compass Therapeutics (NASDAQ:CMPX) from Outperform to Neutral and lowers the price target from $5 to $1.
benzinga.com HC Wainwright & Co. Maintains Buy on Compass Therapeutics, Lowers Price Target to $12 HC Wainwright & Co. analyst Joseph Pantginis maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $24 to $12.
benzinga.com Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gained, financials dropped, and Thor Industries climbed 5%.
benzinga.com Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug Compass Therapeutics, Inc. (NASDAQ:CMPX) shares are trading lower on Tuesday as the FDA feedback raises new questions about the timing and requirements for its tovecimig program.
benzinga.com Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug Compass Therapeutics shares plunge after FDA seeks a survival-benefit trial before tovecimig’s FDA marketing application.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved…
benzinga.com Dow Gains Over 100 Points; AutoZone Posts Upbeat Earnings U.S. stocks rose Tuesday: Dow +0.24%, Nasdaq +0.39%, S&P 500 +0.18%. Communication services led; energy fell. AutoZone beat earnings; oil dropped 2.4%.
globenewswire.com Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics…- benzinga.com Piper Sandler Maintains Overweight on Compass Therapeutics, Raises Price Target to $6 Piper Sandler analyst Biren Amin maintains Compass Therapeutics (NASDAQ:CMPX) with a Overweight and raises the price target from $4 to $6.
benzinga.com Compass Therapeutics Q2 EPS $(0.13) Misses $(0.11) Estimate Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 7.14 percent increase over losses…
globenewswire.com Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior…
benzinga.com Compass Therapeutics Abstract Accepted For Oral Presentation At Upcoming European Society For Medical Oncology Congress Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today…
globenewswire.com Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…
seekingalpha.com Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff. CMPX's lead asset, tovecimig, showed strong PFS benefit in BTC, but OS crossover contamination…
seekingalpha.com Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
marketbeat.com Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win Compass Therapeutics NASDAQ: CMPX Chief Executive Officer Tom Schuetz said the company is preparing for a key U.S. Food and Drug Administration meeting on tovecimig, its DLL4/VEGF bispecific…
globenewswire.com Compass Therapeutics to Participate in Upcoming June Investor Events BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…- benzinga.com Compass Therapeutics' CTX-8371 Dual PD-1/PD-L1 Bispecific Shows Durable Monotherapy Responses In Advanced Checkpoint-Resistant Cancers With Favorable Safety Profile CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with…
globenewswire.com Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…
gurufocus.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX PR Newswire
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. (“Compass” or the “Company”) (NASDAQ: CMPX). Such investors are…
gurufocus.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX PR Newswire
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. (“Compass” or the “Company”) (NASDAQ: CMPX). Such investors are…
globenewswire.com Compass Therapeutics to Participate in Upcoming May Investor Events BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to…- benzinga.com Compass Therapeutics Q1 EPS $(0.10), Inline Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 16.67 percent increase over losses of $(0.12) per share from the…
benzinga.com Canaccord Genuity Maintains Buy on Compass Therapeutics, Lowers Price Target to $7 Canaccord Genuity analyst John Newman maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $13 to $7.- benzinga.com Citizens Reiterates Market Outperform on Compass Therapeutics, Maintains $10 Price Target Citizens analyst Reni J. Benjamin reiterates Compass Therapeutics (NASDAQ:CMPX) with a Market Outperform and maintains $10 price target.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $24 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $24 price target.
benzinga.com Crude Oil Gains Over 1%; Verizon Posts Upbeat Earnings U.S. stocks trade lower on Monday, with Dow falling 0.1%. Verizon beats Q1 earnings, raises FY26 guidance. European shares mixed, Asian markets close mixed.
benzinga.com US Stocks Mixed; Nasdaq Falls Over 100 Points US stocks mixed on Monday, Nasdaq falls 0.56% while Dow gains 0.06%. Energy shares up 1%. Domino's reports worse-than-expected results.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations, shares fall 3.8%. Other stocks also decline.- benzinga.com Market-Moving News for April 27th QCOM: 13% | OpenAI Eyes 'AI Agent' Smartphone With Qualcomm And MediaTek, Targets App-Free Experience By 2028: Report CMPX: -14% | Compass Therapeutics To Host Webcast On April 27 To Review Topline
benzinga.com Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the company for $11.75 billion, $2 higher than current price.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com 9 Health Care Stocks With Whale Alerts In Today's Session 
benzinga.com Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday 
benzinga.com This Linde Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday